Gilead and Tibotec Partner to Develop and Commercialise HIV Combination Drugs
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 7 (Table of Contents)
Published: 6 Jul-2011
DOI: 10.3833/pdr.v2011.i7.1491 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Gilead Sciences and Johnson & Johnson’s Tibotec Pharmaceuticals have agreed to work together to develop a once-daily, single tablet fixed-dose combination of Tibotec’s protease inhibitor Prezista® (darunavir) and Gilead’s pharmacoenhancing agent, cobicistat, for the treatment of HIV-1 infection...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS